至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Development and Validation of a Novel Dual Luciferase Reporter Gene Assay to Quantify Ebola Virus VP24 Inhibition of IFN Signaling.

Viruses. 2018-01; 
FanunzaElisa,FrauAldo,SgarbantiMarco,OrsattiRoberto,CoronaAngela,Tramontano
Products/Services Used Details Operation
Gene Synthesis … Pierce ECL Western Blotting Substrate was from Thermo Fisher Scientific (Waltham, MA, USA). 2.2. Construction of EBOV VP24 Mammalian Expression Plasmid. The EBOV VP24 cDNA was obtained by de novo gene synthesis (GenScript USA Inc … Get A Quote

摘要

The interferon (IFN) system is the first line of defense against viral infections. Evasion of IFN signaling by Ebola viral protein 24 (VP24) is a critical event in the pathogenesis of the infection and, hence, VP24 is a potential target for drug development. Since no drugs target VP24, the identification of molecules able to inhibit VP24, restoring and possibly enhancing the IFN response, is a goal of concern. Accordingly, we developed a dual signal firefly and Renilla luciferase cell-based drug screening assay able to quantify IFN-mediated induction of Interferon Stimulated Genes (ISGs) and its inhibition by VP24. Human Embryonic Kidney 293T (HEK293T) cells were transiently transfected with a lucif... More

关键词

Ebola virus VP24,IFN inhibition,IFN signaling,drug development,dual luciferase gene reporter assay,innate immu